Fig. 7

The personalized RWR scores for 4 biological functions of the BCL-6 gene (left panel) and for the EGFR response to 4 drugs (right panel). Panel A suggests that BCL-6 may have a larger role in inflammation for patients 3 and 5, but a larger role in cartilage development and translational elongation in patient 1. Panel B suggests that the anti-inflammatory drug valdecoxib and the anti-neoplastic drug salirasib may cause a stronger down-regulation of EGFR in patients 1 and 4 versus the others